艾伯维公司 ABBV 深 沪
交易中 03-25 11:44:44 美东时间
208.46
+3.260
+1.59%
华盛通- 最 高209.68
- 今 开206.86
- 成交量 163.86万股
- 最 低 206.26
- 昨 收 205.20
- 总市值 3685.57亿
- 52周最高 241.44
- 市盈率 静 88.29
- 换手率 0.09%
- 52周最低 157.74
- 委 比 90.87%
- 总股本 17.68亿
- 历史最高 241.44
- 量 比 0.46
- 振 幅 1.67%
- 历史最低 -18.61
- 每 手 1
- 风险率 20.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nanobiotix gains after report on J&J buyout bid
Nanobiotix (NBTX) shares rose ~7% in Paris on Wednesday after the French publication La Lettre reported that U.S. pharma giant Johnson & Johnson (JNJ) is eyeing a buyout deal to acquire the cancer dru...
今天 19:03
UPDATE 3-Merck braces for Keytruda patent loss with $6.7 billion Terns bet
UPDATE 3-Merck braces for Keytruda patent loss with $6.7 billion Terns bet Rewrites throughout, adds Merck's shares in paragraph 4, adds analyst comments in paragraphs 8, 13-16 March 25 (Reuters) - Merck MRK.N said on Wednesday it would buy biotech Terns Pharma TERN.O for $6.7 billion, as the drugma
今天 18:54
AbbVie Named Official Pharmaceutical Partner of Major League Baseball
Partnership expands "Striking Out Cancer" campaign beginning on Opening Day AbbVie named Official Pharmaceutical Partner of Major League Baseball (MLB), expanding Striking Out Cancer league-...
03-24 20:00
BUZZ-Xilio rises after surprise quarterly profit
BUZZ-Xilio rises after surprise quarterly profit ** Shares of drug developer Xilio Therapeutics XLO.O rise 3.18% to $8.11 premarket ** Co posts Q4 profit of 81 cents per share, while analysts were expecting loss of $1.68 per share - data compiled by LSEG ** Posts Q4 revenue of $13.7 million vs estim
03-23 20:45
Xilio Therapeutics posts Q4 profit on higher collaboration revenue
Xilio Therapeutics posts Q4 profit on higher collaboration revenue Overview US biotechnology firm's Q4 net income turned positive, driven by higher collaboration and license revenue Operating expenses for Q4 increased year-over-year due to expanded R&D and clinical activities Company extended cash r
03-23 19:38
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
Xilio Therapeutics announced progress on its pipeline, including XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, with plans for IND submission in mid-2026 and Phase 1 initiation in late 2026. The company is advancing masked T cell engager programs targeting PSMA and STEAP1, as well as CLDN18.2, with plans to present preclinical data at AACR in April 2026. Xilio reported a strong cash position of $137.5 million as of December 2025...
03-23 11:30
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
Royalty Pharma appoints Lucas Glass as Head of Artificial Intelligence, effective April 2026. With over a decade of experience in AI and data solutions, Glass will lead the implementation of cutting-edge AI capabilities, enhancing the company's decision-making and operational efficiency. His appointment underscores Royalty Pharma's commitment to leveraging advanced technologies to strengthen its competitive edge in the biopharmaceutical sector.
03-23 11:15
AbbVie Stock Slides as Insider Selling Spooks Investors
AbbVie ( ($ABBV) ) has fallen by -7.40%. Read on to learn why. AbbVie shares fe...
03-21 22:01
国内首个！艾伯维重磅炸弹新适应症申报上市
（来源：求实药社） 3 月 20 日，CDE 官网显示，艾伯维乌帕替尼缓释片的一项新适应症上市申请获得受理，并被纳入优先审评，拟用于治疗成人和 12 岁及以上青...
03-20 17:57
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
RBC Capital Markets has compiled a list of 13 biotechs that are most likely to receive takeover interest, including Revolution Medicines (RVMD), Ascendis Pharma (ASND), and Arrowhead Pharma (ARWR), am...
03-20 02:37
